The multi-center, randomized Pathway M-1 study, which will enroll 30 patients, is designed to assess the safety and efficacy of neurostimulation system for the treatment of migraine.

The company’s neurostimulation system is also currently being assesed in the Pathway CH-1 study for the treatment of cluster headache.

The interim results of the study demonstrated pain relief in 59% of headaches treated.

Autonomic Technologies president and CEO Ben Pless said building on their therapy’s promising results in cluster headache, ATI and their investigator team are excited to begin clinical work with migraine patients.

"We hope that our work may one day offer relief to tens of thousands of severe headache sufferers,"
Pless added.